News
ACAD
16.82
-1.46%
-0.25
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 16h ago
ACADIA PHARMACEUTICALS INC <ACAD.O>: NEEDHAM CUTS TARGET PRICE TO $30 FROM $32
Reuters · 21h ago
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
Barchart · 2d ago
Weekly Report: what happened at ACAD last week (0408-0412)?
Weekly Report · 4d ago
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
ACADIA Pharmaceuticals has an average price target of $33.2. Acadia Pharmaceuticals is a biotechnology company that develops and commercializes drugs for central nervous system disorders. 26 analysts have expressed a variety of opinions on ACADIA pharmaceuticals over the past quarter. The 12-month price targets assessed by analysts show an average of $19.00 for the company.
Benzinga · 04/10 20:01
ACADIA Pharmaceuticals Price Target Maintained With a $37.00/Share by Cantor Fitzgerald
Dow Jones · 04/10 13:44
Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target
Benzinga · 04/10 13:33
ACADIA PHARMACEUTICALS INC <ACAD.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $28 FROM $33
Reuters · 04/10 03:27
Taysha draws bullish view at Piper Sandler on lead asset
Taysha Gene Therapies' lead asset, TSHA-102, targeted at the rare neurodevelopmental disorder Rett syndrome. Piper Sandler has an Overweight recommendation on the stock and a $9 price target. The company's lead asset represents a more than $900M revenue opportunity.
Seeking Alpha · 04/09 19:16
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 04/09 10:40
ACADIA Pharmaceuticals Price Target Maintained With a $32.00/Share by Needham
Dow Jones · 04/09 10:38
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 04/09 02:40
Weekly Report: what happened at ACAD last week (0401-0405)?
Weekly Report · 04/08 09:30
Oversold Conditions For Acadia Pharmaceuticals (ACAD)
NASDAQ · 04/05 20:20
ACADIA PHARMACEUTICALS INC <ACAD.O>: RBC CUTS TARGET PRICE TO $29 FROM $30
Reuters · 04/04 11:41
ACADIA APPOINTS ELIZABETH H. Z. THOMPSON, PH.D. AS EXECUTIVE VICE PRESIDENT, HEAD OF RESEARCH AND DEVELOPMENT
Reuters · 04/02 20:05
Weekly Report: what happened at ACAD last week (0325-0329)?
Weekly Report · 04/01 09:29
Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?
NASDAQ · 03/28 15:30
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
ACADIA Pharmaceuticals burnt through US$23m in the last year. The company is burning through cash to fund its growth. Its revenue growth of 40% over the same period is impressive. ACADIA pharmaceuticals has no debt and is expected to break even soon. We look at the company's cash runway to see if shareholders should be worried about its cash burn.
Simply Wall St · 03/27 18:37
Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers
Seeking Alpha · 03/26 18:13
More
Webull provides a variety of real-time ACAD stock news. You can receive the latest news about Acadia Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.